Engineering a designer immunotherapy

See allHide authors and affiliations

Science  02 Mar 2018:
Vol. 359, Issue 6379, pp. 990-991
DOI: 10.1126/science.aas9434

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution


Understanding of the human immune system has fueled development of numerous drugs, categorized as biologics, designed to mimic or inhibit natural immune responses. Recently, immunoengineering has emerged as a distinct discipline aimed at creating increasingly sophisticated therapeutics that can tailor immune responses for increased potency and/or diminished toxicity. On page 1037 of this issue, Sockolosky et al. (1) test the hypothesis that an engineered interleukin-2 (IL-2)–IL-2 receptor-β (IL-2Rβ) pair can expand effector T cells for cancer immunotherapy while avoiding the toxicities associated with administration of natural IL-2.